Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerPrognostic outlier genes for enhanced prostate cancer treatment.Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease.PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.Should Gleason 6 be labeled as cancer?Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate CancerDisruption of prostate epithelial differentiation pathways and prostate cancer development.Prognostic prostate tissue biomarkers of potential clinical use.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a reviewWhich, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.Prognostic and predictive biomarkers in prostate cancer.Molecular biomarkers to guide precision medicine in localized prostate cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.Tumour heterogeneity poses a significant challenge to cancer biomarker research.PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer.Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC.Emerging biomarkers in the diagnosis of prostate cancer.Advances in prostate cancer research models: From transgenic mice to tumor xenografting models.The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the LiteratureApparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy
P2860
Q26738703-0D78457A-474C-4F4E-AB4F-07DDC27D39B5Q30244674-9A4164F6-DD35-45A5-9228-964536BA2855Q30573750-3FBC4CAA-FC0A-4247-A5E6-86B1D0FAFD53Q33566981-129F22E3-C4DC-41E4-A288-F6F07740D19BQ34998516-5B52FE30-D672-43F3-8F1A-A74F82994942Q35540013-401CD26E-24C8-4A7B-A73D-885B5C15B782Q36753720-B7A73C14-96D6-47E6-BE4E-E2AA3A14FDBBQ36887707-724254C5-41D4-4431-B65A-1CCE9947E3F4Q36931932-07637122-7FE6-4B0B-9686-3E1164ED1724Q37029385-D2F7F289-A27F-4413-A6EB-FF44562A7DD1Q37221588-5DAAEDB5-0B0F-4098-9B8C-2EE897B773A2Q38160495-94726911-DE5D-472D-8A79-CF111D87F47EQ38184382-BE440DDC-A882-4FC8-8F20-CD6A741F311AQ38253055-8C73F6F1-DCCA-4202-B0DD-40B97F785052Q38540198-289F6746-D517-46C1-BAC1-8A59D07E4C85Q38628081-2C1B26D9-58E7-4CD0-A489-3A312E76F042Q38668635-6416A88B-721A-4661-8047-5DC868DFA468Q38774228-33EEAC30-1276-4794-A8A5-42127BAB804EQ38833458-D016EE94-C84F-40AF-BCC6-D4A51E44E27AQ39401816-95C42C59-754B-4382-BA74-BF6537E77EAAQ40919195-00FD56A4-5AA0-48C6-8928-544B0A183FBFQ41004851-E7332811-24C1-4704-8433-A39BD43C0BFCQ41193147-5E17B456-4FE0-4F93-AA3F-9A23B441A7A9Q41912121-C85A1719-E086-476D-9580-26555055378DQ42184292-3320A65A-CC04-42FD-AA11-4BD16C14292EQ42370830-5944CD17-1327-4E1C-BC01-1506A3BACFF7Q42371556-10817854-1E8F-40EB-A3E9-713E8A456B10Q42748239-DC186988-0587-4659-B14C-82A564B2CF48Q42754619-D9238958-0041-4B40-B2C6-9D885E80C489Q43089446-F7643FF7-7BF3-41E9-A70E-200212757774Q47172196-7BD4ACFE-0C96-4E97-88A9-BA03828BA8D8Q47215343-0EBADFDD-1D74-469A-B852-E1759B580CEAQ51549809-59A42B48-2163-4975-A97D-5FA0150FC348Q52655164-3AA06CBB-AB73-4F33-BD0B-C9313259B194Q54964875-2F999229-FC34-421A-8EBE-46F4C28AC30CQ55237889-FE74CD96-6388-45F2-AC5A-23BE09349449Q57073785-7DC12732-EFFE-4337-B2A4-9E67EBE0F23CQ57565054-15382089-44CF-434B-A7BA-D658A93AD044
P2860
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prognostic value of PTEN loss ...... ged localised prostate cancer.
@en
type
label
Prognostic value of PTEN loss ...... ged localised prostate cancer.
@en
prefLabel
Prognostic value of PTEN loss ...... ged localised prostate cancer.
@en
P2093
P2860
P356
P1476
Prognostic value of PTEN loss ...... aged localised prostate cancer
@en
P2093
C S Cooper
D M Berney
E Tikishvili
J S Lanchbury
P Scardino
P2860
P2888
P304
P356
10.1038/BJC.2013.248
P407
P577
2013-05-21T00:00:00Z